Abstract
gBRCA1/2 testing in HER2- ABC is critical to assess eligibility for PARP inhibitors (PARPi). However, testing is heterogeneous across healthcare sectors in Germany. We investigated clinical practice, awareness and availability of routine gBRCA1/2 testing in the German outpatient oncology setting.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
